Apart from traditional eyeglasses and contact lenses, laser-assisted in situ keratomileusis (LASIK) remains the dominant method globally for correcting refractive errors. However, this corneal refractive laser surgery procedure is not ideal, due to the fact that it is invasive, rarely can be repeated, corrects only distance vision and requires a huge capital expenditure.
The View Beyond LASIK: New Techs Further Propel Refractive Surgical Market
LASIK continues to hold a dominant share of the refractive surgical market but limitations in current technologies are stymying further growth. However, a tide of innovation refractive correction is coming in now, and over the next few years that will accelerate growth in this market and fully capitalize on this huge and yet undertapped opportunity known as presbyopia. This article discusses drivers and barriers in the refractive correction market and highlights three companies to look out for this space.
More from Ophthalmology
More from Device Area
• By
Tempering expectations on the immediate market impact for the upgraded continuous glucose monitor, Dexcom notes insurance coverage and pump integrations will take time to finalize.
• By
In response to the Trump administration increasing its tariffs on imports from China, Beijing announced a ban on gene sequencers from US biotech firm Illumina, signaling a full-blown trade war could be in the making. Trump also pushed the deadline for implementing tariffs on Canada and Mexico back by another month.
• By
The US FDA has announced seven device safety actions in recent days. The most serious, which relates to a manufacturing defect in Boston Scientific’s Accolade pacemaker, has been linked to 832 injuries and two deaths.